Salem-based Amplistar, Inc. signed a worldwide licensing agreement with Johns Hopkins University. The agreement will commercialize immunogenic ovarian cancer gene products for both diagnostic and therapeutic purposes. Amplistar is a post-genomics company focused on the identification of antibody target for the early detection and treatment of cancer. Participants may be public or private and encompass all industry segments including biotechnology, semiconductors, Internet, software, and communications. An additional category award called Rising Stars recognizes companies that have been in business three or four years and are on their way to becoming a North Carolina Technology Fast 50 winner.
Companies can nominate themselves, or be nominated by a third party.
Nominations are due by April 27, 2001. Send Web site comments to the CED Webmaster . All rights reserved.